1. Home
  2. SLXN vs WKHS Comparison

SLXN vs WKHS Comparison

Compare SLXN & WKHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • WKHS
  • Stock Information
  • Founded
  • SLXN 2008
  • WKHS 2007
  • Country
  • SLXN Israel
  • WKHS United States
  • Employees
  • SLXN N/A
  • WKHS N/A
  • Industry
  • SLXN
  • WKHS Auto Manufacturing
  • Sector
  • SLXN
  • WKHS Consumer Discretionary
  • Exchange
  • SLXN NYSE
  • WKHS Nasdaq
  • Market Cap
  • SLXN 6.9M
  • WKHS 6.0M
  • IPO Year
  • SLXN N/A
  • WKHS N/A
  • Fundamental
  • Price
  • SLXN $0.92
  • WKHS $0.90
  • Analyst Decision
  • SLXN Strong Buy
  • WKHS Hold
  • Analyst Count
  • SLXN 1
  • WKHS 1
  • Target Price
  • SLXN $5.00
  • WKHS $15.62
  • AVG Volume (30 Days)
  • SLXN 3.6M
  • WKHS 719.5K
  • Earning Date
  • SLXN 05-13-2025
  • WKHS 05-15-2025
  • Dividend Yield
  • SLXN N/A
  • WKHS N/A
  • EPS Growth
  • SLXN N/A
  • WKHS N/A
  • EPS
  • SLXN N/A
  • WKHS N/A
  • Revenue
  • SLXN N/A
  • WKHS $5,917,985.00
  • Revenue This Year
  • SLXN N/A
  • WKHS $76.52
  • Revenue Next Year
  • SLXN N/A
  • WKHS $61.57
  • P/E Ratio
  • SLXN N/A
  • WKHS N/A
  • Revenue Growth
  • SLXN N/A
  • WKHS N/A
  • 52 Week Low
  • SLXN $0.21
  • WKHS $1.03
  • 52 Week High
  • SLXN $13.56
  • WKHS $68.00
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • WKHS 24.05
  • Support Level
  • SLXN N/A
  • WKHS $0.89
  • Resistance Level
  • SLXN N/A
  • WKHS $1.17
  • Average True Range (ATR)
  • SLXN 0.00
  • WKHS 0.07
  • MACD
  • SLXN 0.00
  • WKHS 0.05
  • Stochastic Oscillator
  • SLXN 0.00
  • WKHS 1.79

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

Share on Social Networks: